Protective Immune Response Evokes a Bioengineered RSV Protein Vaccine

Protective Immune Response Evokes a Bioengineered RSV Protein Vaccine ...

Ana Nunez Castrejon, a graduate student of UC Santa Cruz, and a senior professor of biomolecular engineering Rebecca DuBois have recently completed a major milestone in their effort to develop an effective vaccination for the virus thanks to their structure-based design and antigenic validation of respiratory syncytial virus G immunogens in theJournal of Virology.

Nunez Castrejon, a fifth-year Baskin Engineering student and the papers'' lead author, was involved in months of pneumonia, which continued when she was an undergraduate student. During her study, DuBois developed a fascination with respiratory illnesses, causing her to develop severe respiratory infections.

All of these wonderful childhood vaccinations have eliminated so much childhood illness, but there are still a lot of infectious diseases that are very harsh on children, and RSV is one of the many that causes hospitalizations in children, according to DuBois.

The researchers altered the structure of the RSVs G protein to eliminate its negative effects while simultaneously eliciting a protective response from the immune system in the form of antibodies that lie to the G protein.

The researchers2021 expressed their belief that their engineered G protein was able to stimulate a stronger antibody response than the native G protein. However, it was unclear if the engineered G protein still appeared like the native protein on the surface of the virus. The latest findings suggest that this engineered G protein is identical to human RSV-fighting antibodies.

My research shows that the engineered mutation in the protein does not alter antibodies'' ability to bind it, so when it is used as a vaccination antibody, it is possible to elicit these protective antibodies in animal models, and if possible, individuals will be protected from the disease, according to Nunez Castrejon.

This paper is similar to a 2017 publication that influenced the creation of the COVID-19 vaccine that outlined how to bioengineer the coronaviruss Spike antigen to induce more and better antibodies, a strategy that was used to create the Moderna, Pfizer, J&J, and Novavax vaccine antigens. Both papers utilise structural biology to ensure that an adapted version of a virus can be recognized by the immune system to combat the actual virus.

It''s the same kind of foundational work that allowed scientists to develop the coronavirus vaccine so quickly and that it would look exactly like it did on the surface of the virus, according to DuBois. I think some individuals are beginning to realize that we can make vaccinations that stimulate immune responses that are superior to you when it comes to infection, so that we can use antigens in a way that reveals the flaws of the virus.

In their approach to studying the viruses proteins, DuBoiss'' research differs from other research to develop a RSV vaccine. Many researchers are developing a modular RSV F protein, which combines the virus and host cell membranes together to obtain the viruses'' genetic information into cells.

Early-stage clinical trials of vaccinations using this method offer only a 60 to 70 percent protection against infection, which is promising but lower than what would be expected for an important pathogen like RSV.

The researchers are looking to further investigate findings from scientists at the University of Georgia in regards to their engineered protein that affected disease symptoms in mice, and will continue to design the RSV G protein to enhance immune responses in the future five years. They intend to develop an RSV vaccine using their engineered protein that is ready for clinical trials.

DuBois and Castrejon Nunez have teamed up together to develop monoclonal antibodies for the treatment of infants with RSV infection and severe lung congestion.

You may also like: